Medicare Part D premiums may look stable on the surface—averaging $34.50 per month in 2026, down from $38 in 2025—but beneath that headline number lies a troubling reality. The underlying cost of Part D coverage increased by a staggering 35 percent from 2025 to 2026, jumping $75.38 before subsidies. That enormous hidden increase was masked by a temporary federal stabilization subsidy that shrank from $15 per month to just $10 per month.
For millions of retirees already stretching fixed Social Security checks, this is the real story: drug coverage is becoming less affordable, even as the advertised premiums appear to decline. The numbers are worse than you think because they tell two completely different stories depending on which metrics you examine. While the front-page premium numbers might seem manageable, the out-of-pocket costs you’ll actually pay at the pharmacy, the deductibles climbing higher, and the affordability crisis affecting nearly two-thirds of Medicare households paint a far grimmer picture. A beneficiary taking three chronic medications per month—common for someone managing diabetes, hypertension, and arthritis—could easily face $200 to $400 in monthly out-of-pocket costs once they hit the coverage gap, on top of whatever premium they pay.
Table of Contents
- Why Are Medicare Part D Costs Exploding Even as Premiums Appear Stable?
- The Out-of-Pocket Costs Are Climbing While Incomes Stay Frozen
- The Chronic Medication Burden Keeps Growing as Drug Costs Spiral
- Drug Price Negotiation Is Delivering Real Savings—But Only for a Few Medications
- The Premium Subsidy Reduction is a Silent Cliff Edge Approaching
- New GLP-1 Coverage Opens Access but Raises New Affordability Questions
- What 2027 Will Bring—And Why Long-Term Reform Still Lags
- Conclusion
Why Are Medicare Part D Costs Exploding Even as Premiums Appear Stable?
The gap between advertised Part D premiums and actual cost growth reveals a system under extreme pressure. Three-year data shows per-enrollee costs increased 20 percent in 2024, then 42 percent in 2025, and 35 percent in 2026. Simultaneously, prescription drug spending across the entire U.S. economy grew by 11.4 percent in 2024, compared to just 4.9 percent in 2023—meaning drug price inflation itself is accelerating.
This one-two punch of rising drug prices and aging beneficiary populations creates a mathematical problem that no subsidy can permanently solve: costs are rising much faster than the subsidies designed to hide them. The premium stabilization demonstration, which limited how much insurance companies could raise premiums, reduced from $15 monthly in 2025 to $10 in 2026 and now caps increases at $50 per plan. Without this artificial cap, many beneficiaries would have seen their premiums jump far more dramatically. But the subsidy reduction reveals the uncomfortable truth: the federal government is slowly withdrawing its financial cushion. Once this demonstration ends, expect premiums to rise substantially as plans are no longer held back from passing full costs to consumers.
The Out-of-Pocket Costs Are Climbing While Incomes Stay Frozen
The annual out-of-pocket cap—the maximum you’ll pay for Part D drugs in a calendar year—climbed from $2,000 in 2025 to $2,100 in 2026, a $100 jump. The maximum deductible rose from $590 to $615. These numbers might seem modest, but they compound a devastating affordability problem: half of all Medicare beneficiaries live on $43,200 or less per year, and one-quarter have less than $18,950 in total savings. For someone living on $3,600 monthly, a $2,100 out-of-pocket drug cost represents 58 percent of monthly income before food, rent, or utilities. The initial coverage phase is where most beneficiaries see this pain firsthand.
In that phase, you pay 25 percent of drug costs while Part D covers the other 75 percent. This sounds reasonable until you realize that your 25 percent share is based on the negotiated price—which has soared. For a drug with a $400 monthly cost, your quarter-share is $100, not including the deductible you paid upfront. Multiply that by three to five medications per month, and the arithmetic becomes brutal quickly. One-third of Medicare beneficiaries delayed or skipped medications or medical care in 2023 due to cost concerns, and there’s no evidence this number has improved.
The Chronic Medication Burden Keeps Growing as Drug Costs Spiral
Over two-thirds of Medicare beneficiaries have multiple chronic conditions requiring ongoing pharmaceutical management. The typical Part D enrollee takes four to five prescriptions per month—this isn’t theoretical; it’s the standard reality for someone age 75+ managing hypertension, diabetes, arthritis, heart disease, and osteoporosis simultaneously. With average per-enrollee costs up 35 percent year-over-year, the cumulative out-of-pocket cost of managing multiple chronic conditions is now in the thousands of dollars annually for most retirees.
A concrete example: A 72-year-old managing hypertension, diabetes, and atrial fibrillation might take lisinopril, metformin, and warfarin—three relatively inexpensive generics. But when her doctor adds a newer diabetes drug or a statin for cholesterol, her costs can jump by $150 to $300 per month even with insurance. If she falls into the coverage gap (the “donut hole” between initial coverage and catastrophic coverage), she’s paying full negotiated prices until her out-of-pocket spending hits $2,100. The warning here is clear: if you have multiple chronic conditions and take brand-name drugs, you will almost certainly hit the coverage gap, and you need to plan accordingly.
Drug Price Negotiation Is Delivering Real Savings—But Only for a Few Medications
The Medicare drug price negotiation program represents genuine progress, yet it affects only a sliver of the overall problem. Ten drugs were selected for negotiated pricing in 2026, with discounts ranging from 38 percent to 79 percent off 2023 list prices. The result: nearly 9 million enrollees are expected to save $1.5 billion, with out-of-pocket costs declining by approximately 50 percent on average for those specific drugs. For someone taking one of these ten medications, the relief is substantial and real—perhaps saving $30 to $60 per month.
However, here’s the limitation: Medicare Part D covers thousands of drugs, and only ten have negotiated prices. If you take medications outside this select list—and most beneficiaries do—you see none of this benefit. Fifteen additional drugs are set for negotiation in 2027, which will provide more savings, but the program is expanding far too slowly to keep pace with the overall cost crisis. A beneficiary whose doctor prescribes an off-the-list brand-name drug receives no negotiation benefit and faces the full brunt of inflation. The message for retirees: ask your doctor explicitly whether you’re taking any of the ten 2026 negotiated drugs or the upcoming 2027 list before assuming you’ll see savings.
The Premium Subsidy Reduction is a Silent Cliff Edge Approaching
The $5 monthly reduction in the stabilization subsidy from 2025 to 2026 seems minor, but it signals a larger withdrawal. That subsidy was temporary, created as part of the 2022 Inflation Reduction Act to make Part D more affordable. Temporary subsidies don’t last forever, and when they expire, premiums face the full weight of cost increases. For a beneficiary currently enjoying a $34.50 monthly premium thanks to $10 in federal subsidy, a future premium might be $50, $60, or higher once that cushion disappears.
The warning embedded in this data is unavoidable: anyone planning finances for the next five to ten years should not assume Part D premiums will remain stable or decline. Expect double-digit annual increases once the demonstration period ends. The plan cap of $50 monthly increases sounds generous until your premium jumps from $35 to $85 in a single year. For retirees on fixed incomes, this type of cliff is catastrophic because Social Security cost-of-living adjustments rarely keep pace with Part D premium jumps.
New GLP-1 Coverage Opens Access but Raises New Affordability Questions
Effective July 1, 2026, Medicare Part D will cover certain GLP-1 drugs (like semaglutide) with a $50 copayment for a monthly supply. This is genuinely significant—GLP-1 drugs cost $900 to $1,500 monthly without insurance, and now beneficiaries can access them with predictable copays. For someone with Type 2 diabetes or obesity-related health conditions, this change could be life-changing.
The catch: this new coverage doesn’t eliminate the underlying cost pressures on Part D. The addition of expensive GLP-1 coverage will pull more people into higher cost-sharing phases and may contribute to premium increases down the road. The benefit is real and valuable, but it’s being added to a system already straining under 35 percent annual cost increases. In other words, better coverage for one drug class doesn’t solve the fundamental affordability problem affecting millions of beneficiaries on other medications.
What 2027 Will Bring—And Why Long-Term Reform Still Lags
The second round of drug price negotiations will affect 15 additional drugs in 2027, with estimated savings of $8.5 billion to $12 billion annually. This is progress, but at the current pace of expansion, it will take decades to negotiate meaningful reductions across the thousands of drugs in Part D’s formularies. Meanwhile, underlying drug price inflation continues at double the rate of general inflation, meaning negotiated savings will be eroded by new price increases almost as soon as they’re locked in.
Looking ahead, the structural problem remains unaddressed: Part D is a system where private insurance companies manage the benefit, drug manufacturers control pricing, and beneficiaries absorb the shock of rapid cost increases. The negotiation program is a bridge—valuable but insufficient. Retirees need to prepare for higher out-of-pocket costs, plan medication needs carefully with their doctors, and explore whether they qualify for extra help programs or Medicaid coverage that could offset Part D costs. The numbers being worse than you think isn’t hyperbole—it’s the inevitable outcome of a system where costs are rising 35 percent annually and subsidies are being withdrawn.
Conclusion
The real story of Medicare Part D in 2026 is hidden beneath deceptive headline numbers. While premiums appear stable, the underlying costs have increased 35 percent, out-of-pocket caps are rising, and the federal subsidies masking these increases are quietly shrinking. Nearly two-thirds of Medicare households worry about affording health care, half of beneficiaries live on under $43,200 annually, and one-third have previously delayed or skipped medications due to cost. The drug price negotiation program offers genuine relief for ten medications now and fifteen more in 2027, but these gains affect only a narrow slice of Part D beneficiaries and do nothing to address the acceleration of drug price inflation across the entire system. If you’re nearing Medicare eligibility or already enrolled, the time to act is now.
Review your current medications and ask which ones fall on the negotiated drug lists. Work with your doctor to identify generic alternatives wherever possible. Calculate your expected out-of-pocket costs under your current plan using Medicare’s official tools. If you qualify for Medicare Savings Programs or extra help, apply immediately—the money left on the table by beneficiaries who don’t apply is substantial. Finally, accept that Part D costs will likely increase significantly over the next five years as temporary subsidies end. Plan accordingly, and adjust your retirement budget upward for prescription drug costs sooner rather than later.